Sildenafil for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: A Phase I/II Randomized Clinical Trial, SILDAT-TAHA6 Trial.

Armin AttarMasoumeh HeydariFiroozeh Abtahi Alireza Rezvani Shirin Haghighat Reza Vojdani Mani Ramzi Mehdi Dehghani Mojtaba KarimiMohammad KasaeiShahdad KhosropanahMahmood Tabandeh

Published in: Cardiology research and practice (2022)

Consumption of sildenafil for primary prevention of anthracycline-induced cardiac toxicity seems to be unbeneficial. This trial is registered with IRCT20180506039554N1.

Keyphrases

diabetic rats
high glucose
study protocol
oxidative stress
pulmonary hypertension
clinical trial
phase iii
left ventricular
pulmonary arterial hypertension
phase ii
randomized controlled trial
drug induced
heart failure
open label